Banai S, Wolf Y, Golomb G, Pearle A, Waltenberger J, Fishbein I, Schneider A, Gazit A, Perez L, Huber R, Lazarovichi G, Rabinovich L, Levitzki A, Gertz S D
Heiden Department of Cardiology, Bikur Cholim Hospital, Jerusalem, Israel.
Circulation. 1998 May 19;97(19):1960-9. doi: 10.1161/01.cir.97.19.1960.
Signaling through protein tyrosine kinases (PTKs) is a major contributor to the transmission of mitogenic stimuli to the interior of the cell and nucleus. The present study was designed to determine the effect of the tyrphostin AG1295, a selective blocker of PDGF-receptor PTK, on the growth of porcine and human smooth muscle cells (SMCs) in culture, on the outgrowth kinetics of SMCs from porcine and human arterial explants, and on neointimal formation after balloon injury in pigs.
SMCs for culture were obtained from porcine abdominal aortas, human internal mammary arteries, and endarterectomy tissue from a single human carotid artery. Addition of AG1295 to SMCs before PDGF stimulation completely inhibited PDGF-beta-receptor tyrosine phosphorylation without affecting the level of PDGF-beta-receptor. AG1295 resulted in a selective, reversible inhibition of SMC proliferation in culture (76%) with only mild (13.5%) inhibition of endothelial cell proliferation. The number of SMCs accumulating around explants of porcine carotid arteries and human endarterectomy specimens 12, 15, 19, 22, and 24 days after plating was reduced by 82% to 92% in AG1295-treated compared with nontreated specimens, and initiation of SMC outgrowth was markedly delayed. The numbers of cells accumulated 10 days after initiation of outgrowth were significantly lower in treated versus control explants. Local intravascular delivery of AG1295-impregnated polylactic acid-based nanoparticles (130+/-25 nm) to the site of balloon injury to porcine femoral arteries resulted in significant reductions in intima/media area ratio and luminal cross-sectional area narrowing by neointima compared with contralateral control arteries to which empty nanoparticles were applied (0.15+/-0.07 versus 0.09+/-0.03, P=.046 and 20+/-4% versus 10+/-4%, P=.0009, n=6 for both).
The tyrphostin AG1295, a selective blocker of PDGF-receptor kinase, exerts a marked inhibitory effect on the activation, migration, and proliferation of porcine and human SMCs in vitro and an approximately 50% inhibitory effect on neointimal formation after balloon injury in porcine femoral arteries when delivered via biodegradable nanoparticles. Further studies appear to be warranted to evaluate the applicability of this novel approach to the interventional setting.
蛋白酪氨酸激酶(PTK)信号传导是将促有丝分裂刺激传递至细胞内部和细胞核的主要因素。本研究旨在确定血小板衍生生长因子受体PTK的选择性阻滞剂 tyrphostin AG1295对培养的猪和人平滑肌细胞(SMC)生长、猪和人动脉外植体中SMC的生长动力学以及猪球囊损伤后新生内膜形成的影响。
用于培养的SMC取自猪腹主动脉、人乳内动脉以及取自单个人颈动脉的动脉内膜切除术组织。在血小板衍生生长因子(PDGF)刺激前向SMC中添加AG1295可完全抑制PDGF-β受体酪氨酸磷酸化,而不影响PDGF-β受体水平。AG1295导致培养的SMC增殖受到选择性、可逆性抑制(76%),而对内皮细胞增殖仅有轻度抑制(13.5%)。与未处理标本相比,在接种后12、15、19、22和24天,AG1295处理的猪颈动脉外植体和人动脉内膜切除术标本周围积累的SMC数量减少了82%至92%,并且SMC生长的起始明显延迟。在生长起始10天后积累的细胞数量,处理组外植体明显低于对照组。将负载AG1295的聚乳酸基纳米颗粒(130±25 nm)局部血管内递送至猪股动脉球囊损伤部位,与应用空纳米颗粒的对侧对照动脉相比,可显著降低内膜/中膜面积比和新生内膜导致的管腔横截面积狭窄(分别为0.15±0.07对0.09±0.03,P = 0.046;20±4%对10±4%,P = 0.0009,两组n均为6)。
tyrphostin AG1295作为PDGF受体激酶的选择性阻滞剂,对猪和人SMC在体外的激活、迁移和增殖具有显著抑制作用,并且通过可生物降解纳米颗粒递送时,对猪股动脉球囊损伤后新生内膜形成具有约50%的抑制作用。似乎有必要进行进一步研究以评估这种新方法在介入治疗中的适用性。